Menu

Recent Interviews

Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

emichael@solgold.com.au

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company


Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)

office@deep-nature.at

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain


01. September 2020 | 11:56 CET

BioNTech, CureVac, Valeo Pharma - COVID-19 wakes up the industry

  • Covid-19

In the past, people have accepted that it usually takes about ten years to get a vaccine on the market. Careful testing with proof of success is required for a preparation to receive approvals. Since COVID-19, the pressure to develop has increased dramatically and also the potential to close a lucrative deal, because a lot is at stake for politics and economy. The necessary tests are carried out at great expense in order not to endanger human life through a vaccination, but to protect it. There are great opportunities for investors.

time to read: 2 minutes by Mario Hose


 

COVID-19 product before market launch

Valeo Pharma is a Canadian pharmaceutical company that claims to manufacture specialty pharmaceuticals and focuses on marketing innovative prescription products in its home country. Valeo Pharma primarily manufactures products for neurodegenerative diseases, oncology products and specialty products for hospitals. The company also has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

Last week, the company released information about the launch of Hesperco in Canada. The product was developed by Ingenew Pharma and will be marketed by Valeo Pharma. Ingenew is a biopharmaceutical company focused on addressing unmet medical needs and serving patients and families affected by serious and debilitating illness. Its primary therapeutic areas of interest include oncology, neurology, urology and dermatology.

Hesperco is a trademark of Ingenew Pharma and will be used by Valeo Pharma under a license agreement. Commenting on the partnership with Valeo, Pierre Laurin, CEO of Ingenew, said: "There is a strong scientific and medical rationale for the use of Hesperco capsules to support the immune system and potentially fight off symptoms associated with Corona viruses such as the one that causes COVID-19. Thousands of compounds have been evaluated since the start of the pandemic and the active compound in Hesperco capsules has been repeatedly reported to be one of the best candidates to interfere with the mechanisms SARS-CoV-2 uses to infect our cells. (…)"

The Valeo team is obviously ready to market the product as soon as possible. "Pending Health Canada's approval, we are poised to proceed with the commercialization of Hesperco capsules," Valeo Pharma CEO Steve Saviuk recently stated in a press release, and continued: "Ingenew's ongoing expansion of scientific data as well as the development of new clinical data will provide further evidence of Hesperco'sTM effectiveness in providing support for the immune system." Investors in Valeo Pharma can benefit from the fact that the company's market capitalization is still well below EUR 100 million and that its potential is correspondingly high, mainly because the company does not take costly research risks but focuses on the commercialization of successful products.

Sustainable success for the post-Corona era

BioNTech from Germany has been in the focus of investors since the beginning of the Corona Pandemic because the company's researchers are excellently positioned to research a vaccine. It is therefore not surprising that the share has been actively traded in recent months and that the market capitalization is already in the double-digit billion range. The business with the COVID-19 vaccine will certainly also have an impact on other research areas of the company and establish new standards in the fight against cancer in the wake of the Corona Pandemic.

Stock market launch thanks to COVID-19

CureVac is also a German company that has made it to the world stage of the pharmaceutical industry in recent months thanks to COVID-19. The company's market value skyrocketed after the company went public. In the race for a vaccine against the Corona virus, investors may be investing according to the watering can principle in order to be among the winners. The term winner in the context of a deadly Pandemic sounds bizarre, but ultimately COVID-19 is currently making the industry faster and more efficient and bringing new stars like CureVac to the scene.


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

23. September 2020 | 09:05 CET

BioNTech, CureVac, or Valeo Pharma: who brings the highest return to shareholders?

  • Covid-19

When the Corona Pandemic started in November 2019 in Wuhan, China, nobody could have guessed the extent of the disease. Socially, economically and politically, Covid-19 has turned the world upside down. With increasing knowledge in dealing with the coronavirus, people around the globe are trying to come to terms with the new state of affairs - as best they can. On the stock market, there are numerous opportunities for investors to participate in further development in the fight against serious diseases.

Read

18. September 2020 | 06:00 CET

BioNTech, CureVac, EXMceuticals - reaching their goal with government support

  • Covid-19

In the fight against the spread of the Corona Pandemic, a great deal of commitment is required from companies. This situation also offers the opportunity to rethink and change existing work processes and procedures. Product ranges are being expanded and new possibilities and active ingredients are being sought to combat Covid-19. Above all, the common good of all is the primary focus of political institutions and for this reason they are not letting research-based companies down and are attracting them with special permits and subsidies. Ultimately, everyone around the world will likely benefit from this.

Read

11. September 2020 | 09:59 CET

BioNTech, CureVac, Valeo Pharma - Growth after capital injection

  • Covid-19

Anyone working in the medical sector knows that the development of therapies and products usually costs a lot of time and especially a lot of money. In the race against the spread of the current Corona pandemic, there are major changes in the industry, because whoever comes to the market with a product first is de facto guaranteed high sales and profits. However, there is not much time left for the development of a vaccine against Covid-19 and to reduce the economic damage, researching companies have virtually unlimited amounts of money available. Whoever finds a solution against Covid-19 will certainly have the right team in the starting blocks in the fight against the subsequent Corona viruses.

Read